Product image of Osteomel Once Weekly (Alendronic Acid) supplied by GNH India

Osteomel Once Weekly

Active Ingredient:
Alendronic Acid
Origin:
EU

Osteomel Once Weekly (Alendronic Acid)

Alendronic acid, the active ingredient in Osteomel Once Weekly, is a bisphosphonate presented as a tablet for oral use. It treats osteoporosis in postmenopausal women and men at risk of fracture. GNH India supplies Osteomel Once Weekly as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Osteomel Once Weekly as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Clonmel Healthcare Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Osteomel Once Weekly is a bisphosphonate that acts on bone metabolism to reduce fracture risk.

  • Post‑menopausal osteoporosis: helps reduce the incidence of vertebral and non‑vertebral fractures.
  • Male osteoporosis: improves bone mineral density and lowers fracture incidence.
  • Glucocorticoid‑induced osteoporosis: mitigates bone loss associated with long‑term steroid therapy.

How It Works

  • Alendronic acid binds selectively to hydroxyapatite crystals on bone surfaces undergoing active remodeling. When osteoclasts attach to these sites, the drug is internalized and inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, disrupting prenylation of essential proteins and leading to reduced osteoclast-mediated bone resorption.

Side Effects

Adverse reactions to alendronic acid are generally dose‑related and may vary in frequency.

Common Side Effects

  • Gastrointestinal irritation: dyspepsia, abdominal pain, or heartburn.
  • Musculoskeletal pain: bone, joint or muscle aches.
  • Esophageal discomfort: mild soreness or ulceration.
  • Nausea or vomiting.
  • Headache.
  • Transient flu‑like symptoms.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw (ONJ).
  • Atypical femoral fractures.
  • Severe esophageal ulceration or perforation.
  • Acute phase reactions with fever and severe bone pain.
  • Hypocalcemia.
  • Renal impairment with prolonged high‑dose exposure.

Precautions & Warnings

When using Osteomel Once Weekly, several safety considerations should be observed.

  • Assess renal function: avoid use in patients with severe renal impairment.
  • Verify calcium and vitamin D status: ensure adequate supplementation before therapy.
  • Review gastrointestinal history: caution in patients with esophageal disorders.
  • Counsel on proper administration: take with a full glass of water, remain upright for at least 30 minutes.
  • Monitor for signs of ONJ: advise dental examination before starting.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Alendronic acid may interact with several concomitant medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Calcium supplements or antacids taken simultaneously: can markedly reduce absorption of alendronic acid.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal irritation.

Moderate Interactions (Monitor Closely)

  • Proton pump inhibitors (PPIs): may affect gastric pH and alter drug absorption.
  • Corticosteroids: additive risk for osteonecrosis of the jaw.
  • Loop diuretics: may exacerbate hypocalcemia.
  • Thyroid hormone replacement: monitor calcium levels.
  • Vitamin D analogues: adjust dosing based on serum levels.

Frequently Asked Questions

Osteomel Once Weekly contains alendronic acid, a bisphosphonate indicated for the treatment and prevention of osteoporosis in post‑menopausal women, men at risk of fracture, and patients receiving long‑term glucocorticoid therapy. It helps increase bone mineral density and reduce the risk of vertebral and non‑vertebral fractures.

Alendronic acid binds to bone mineral at sites of active remodeling. When osteoclasts attempt to resorb bone, the drug is taken up and inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting protein prenylation and ultimately reducing osteoclast activity and bone resorption.

The dosing regimen for Osteomel Once Weekly is determined by the prescribing clinician based on the patient’s condition, renal function, and overall risk profile. The prescriber will specify the exact weekly dose and any necessary administration instructions.

Alendronic acid is generally contraindicated in pregnancy because it can cross the placenta and affect fetal bone development. It is also not recommended while breastfeeding, as it may be excreted in milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatments with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, providing the required quantity and your institutional credentials. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Osteomel Once Weekly is a weekly oral bisphosphonate, offering a convenient dosing schedule compared with daily or monthly alternatives. Compared with intravenous bisphosphonates, it avoids infusion‑related reactions but requires strict adherence to administration instructions to minimise gastrointestinal irritation.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

The tablet is taken orally with a full glass of water, preferably on an empty stomach, at least 30 minutes before any food, drink, or other medication. After swallowing, remain upright for at least 30 minutes to reduce the risk of esophageal irritation.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe esophageal ulceration, and acute renal impairment. Patients should be monitored for persistent jaw pain, unusual thigh or groin pain, and any signs of gastrointestinal bleeding.

Patients with severe renal impairment (creatinine clearance <35 mL/min), known hypersensitivity to alendronic acid or other bisphosphonates, active esophageal disorders, or those unable to follow the required administration protocol should avoid using Osteomel Once Weekly.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Alendronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT